Market Views – Page 21 – media

J&J attracts Chinese interest for diabetes business in potential $3B to $4B deal

Chinese bidders are circling a diabetes care business owned by the world's largest health-care company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters.
- Source: Cnbc;
- 497
- January 19, 2018
diabetes Market Views
Stimwave scoops $50M to step up pain device sales push

Stimwave has raised $50 million to support commercialization of its neuromodulation pain therapies. The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
- Source: fiercebiotech
- 615
- January 19, 2018
Market Views neuromodulation pain therapies Series
AI funding tops $1 billion mark as mobile investments wane

Health IT funding set a record in 2017 with AI and predictive analytics as top tech funded, with patient engagement, telehealth and clinical decision support close behind.
- Source: Healthcare IT News
- 843
- January 19, 2018
AI digital health healthcare technology Market Views
Adoption of cloud-based imaging informatics tools set to accelerate

According to the Frost & Sullivan study, the total revenue of the global cloud-based medical imaging informatics market is expected to remain on a very strong growth trajectory over the next few years, growing from $285.4 million in 2016 to $830.5 million in 2021. That's a significant compound annual growth rate of 23.8 percent.
- Source: Healthcare IT news
- 463
- January 16, 2018
health IT imaging Market Views
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven

After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with a fresh pact with Stanford spinout Forty Seven.
- Source: Endpts;
- 381
- January 15, 2018
Market Views PD-L1 combos
Alveo Closes $38 Million in Series A Financing to Create Accessible Diagnostics Devices

Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
- Source: Prnewswire
- 409
- January 15, 2018
infectious diseases Market Views Series
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 515
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
Is the $850,000 price tag for a blindness-curing gene therapy a sign of future medical costs?

Gene therapies are an undeniably exciting new frontier for medicine. From Kymriah's genetically modified, cancer-hunting immune cells, to Luxturna's vision-restoring healthy gene replacement, these therapies are fundamentally unlike 20th-century medicines which generally require ongoing drug treatment. Gene therapies can be one-off doses that in effect, cure a specific disease.
- Source: New Atlas
- 452
- January 11, 2018
FDA Gene therapy Market Views
Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

Gossamer Bio is launching with $100 million in seed financing and two biotech heavy hitters as leadership.
- Source: drugdu
- 494
- January 10, 2018
Crohn’s disease Market Views multiple sclerosis Series ulcerative colitis
How doctors and bots can work together

The fear that machines will replace humans in the workplace is not a new one. In 1930, economist John Maynard Keynes conjectured that in the years to come, modern economies would face a new kind of affliction: what Keynes called “technological unemployment.”
- Source: Venturebeat
- 544
- January 10, 2018
AI digital health Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.